Amarin Cuts Costs by $70M Annually as International Expansion Drives Demand Growth
Event summary
- Amarin's Q2 2026 revenue fell 42% YoY to $42.2M, primarily due to the absence of a $25M upfront payment from Recordati in Q2 2025.
- Operating expenses dropped 59% YoY to $27M, completing a $70M annual cost savings initiative.
- Global partner demand for VASCEPA/VAZKEPA rose 59% YoY, with Europe up 69% and China up 90% year-to-date.
- U.S. market share increased to 48% from 43% in Q2 2025, despite generic competition.
- Cash position grew to $314.6M as of June 30, 2026, with expectations of a 10% increase by year-end.
The big picture
Amarin's strategic pivot to a fully partnered international model is showing early signs of success, with demand growth offsetting revenue declines from the absence of prior licensing payments. The company's aggressive cost-cutting has positioned it for profitability, but sustaining momentum in Europe and navigating U.S. generic competition remain critical. With cardiovascular disease burdening 62 million people in Europe alone, Amarin's ability to expand VAZKEPA's reach could drive long-term growth.
What we're watching
- Execution Risk
- Whether Amarin can sustain international demand growth amid pricing and reimbursement challenges in Europe.
- Market Dynamics
- How U.S. generic competition will impact VASCEPA's market share and pricing power.
- Strategic Shifts
- The pace at which Amarin explores additional pathways to enhance shareholder value with Barclays' support.
Related topics